GDTC
CytoMed Therapeutics LimitedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.23
P/S
48.18
EV/EBITDA
-5.16
DCF Value
$0.33
FCF Yield
-18.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
109.7%
Operating Margin
-861.8%
Net Margin
-1082.5%
ROE
-47.9%
ROA
-42.5%
ROIC
-36.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $105.7K | $-882.3K | $-0.07 |
| Q1 2025 | $100.0K | $-835.0K | $-0.07 |
| Q4 2024 | $52.4K | $-1.1M | $-0.09 |
| FY 2024 | $52.0K | $-1.9M | $-0.16 |
Company Info
Sector
Healthcare
Industry
—
Country
SG
Exchange
NASDAQ
Beta
-0.35
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.